Header Logo

Connection

JORGE E CORTES to Leukemia, Lymphocytic, Chronic, B-Cell

Back to Details
This is a "connection" page, showing publications JORGE E CORTES has written about Leukemia, Lymphocytic, Chronic, B-Cell.
JORGE E CORTES
Connection Strength
0.866
Leukemia, Lymphocytic, Chronic, B-Cell
  1. Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer. 2001 Oct 15; 92(8):2016-22.
    View in: PubMed
    Score: 0.081
  2. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget. 2017 Mar 28; 8(13):22104-22112.
    View in: PubMed
    Score: 0.059
  3. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood. 2014 Nov 13; 124(20):3059-64.
    View in: PubMed
    Score: 0.050
  4. Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1390-8.
    View in: PubMed
    Score: 0.049
  5. Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia? Biol Blood Marrow Transplant. 2014 Mar; 20(3):421-4.
    View in: PubMed
    Score: 0.047
  6. Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol. 2011 Nov 01; 29(31):4088-95.
    View in: PubMed
    Score: 0.041
  7. Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia. Cancer. 2011 Jul 15; 117(14):3182-6.
    View in: PubMed
    Score: 0.039
  8. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica. 2011 Jan; 96(1):62-8.
    View in: PubMed
    Score: 0.038
  9. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol. 2009 Apr 01; 27(10):1637-43.
    View in: PubMed
    Score: 0.034
  10. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer. 2008 Oct 01; 113(7 Suppl):1933-52.
    View in: PubMed
    Score: 0.033
  11. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008 Aug 15; 112(4):975-80.
    View in: PubMed
    Score: 0.032
  12. Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia. Clin Infect Dis. 2008 Apr 01; 46(7):e69-71.
    View in: PubMed
    Score: 0.032
  13. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors. Br J Haematol. 2007 Mar; 136(6):800-5.
    View in: PubMed
    Score: 0.030
  14. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007 Jun 01; 109(11):4679-85.
    View in: PubMed
    Score: 0.029
  15. A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer. 2006 Jan 15; 106(2):337-45.
    View in: PubMed
    Score: 0.027
  16. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20; 23(18):4070-8.
    View in: PubMed
    Score: 0.026
  17. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20; 23(18):4079-88.
    View in: PubMed
    Score: 0.026
  18. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004 Sep 01; 101(5):999-1008.
    View in: PubMed
    Score: 0.025
  19. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 2003 Dec 15; 98(12):2657-63.
    View in: PubMed
    Score: 0.024
  20. Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol. 2003 Sep; 52(3):223-8.
    View in: PubMed
    Score: 0.023
  21. A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. Br J Haematol. 2003 May; 121(4):578-85.
    View in: PubMed
    Score: 0.023
  22. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003 Apr 01; 97(7):1711-20.
    View in: PubMed
    Score: 0.023
  23. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma. 2002 Apr; 43(4):767-72.
    View in: PubMed
    Score: 0.021
  24. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001 Apr 15; 19(8):2165-70.
    View in: PubMed
    Score: 0.020
  25. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001 Mar 01; 19(5):1414-20.
    View in: PubMed
    Score: 0.019
  26. Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):292-5.
    View in: PubMed
    Score: 0.011
  27. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003 Aug 15; 98(4):773-8.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.